These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

154 related articles for article (PubMed ID: 33171534)

  • 1. Systematic review: Investigating the prognostic performance of four non-invasive tests in alcohol-related liver disease.
    Rhodes FA; Trembling P; Panovska-Griffiths J; Tanwar S; Westbrook RH; Rodger A; Rosenberg WM
    J Gastroenterol Hepatol; 2021 Jun; 36(6):1435-1449. PubMed ID: 33171534
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Non-invasive diagnostic assessment tools for the detection of liver fibrosis in patients with suspected alcohol-related liver disease: a systematic review and economic evaluation.
    Stevenson M; Lloyd-Jones M; Morgan MY; Wong R
    Health Technol Assess; 2012; 16(4):1-174. PubMed ID: 22333291
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Accuracy of the Enhanced Liver Fibrosis Test vs FibroTest, Elastography, and Indirect Markers in Detection of Advanced Fibrosis in Patients With Alcoholic Liver Disease.
    Thiele M; Madsen BS; Hansen JF; Detlefsen S; Antonsen S; Krag A
    Gastroenterology; 2018 Apr; 154(5):1369-1379. PubMed ID: 29317276
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Referral pathways for patients with NAFLD based on non-invasive fibrosis tests: Diagnostic accuracy and cost analysis.
    Crossan C; Majumdar A; Srivastava A; Thorburn D; Rosenberg W; Pinzani M; Longworth L; Tsochatzis EA
    Liver Int; 2019 Nov; 39(11):2052-2060. PubMed ID: 31332938
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Assessment of asymptomatic liver fibrosis in alcoholic patients using fibroscan: prospective comparison with seven non-invasive laboratory tests.
    Nguyen-Khac E; Chatelain D; Tramier B; Decrombecque C; Robert B; Joly JP; Brevet M; Grignon P; Lion S; Le Page L; Dupas JL
    Aliment Pharmacol Ther; 2008 Nov; 28(10):1188-98. PubMed ID: 18705692
    [TBL] [Abstract][Full Text] [Related]  

  • 6. New sequential combinations of non-invasive fibrosis tests provide an accurate diagnosis of advanced fibrosis in NAFLD.
    Boursier J; Guillaume M; Leroy V; Irlès M; Roux M; Lannes A; Foucher J; Zuberbuhler F; Delabaudière C; Barthelon J; Michalak S; Hiriart JB; Peron JM; Gerster T; Le Bail B; Riou J; Hunault G; Merrouche W; Oberti F; Pelade L; Fouchard I; Bureau C; Calès P; de Ledinghen V
    J Hepatol; 2019 Aug; 71(2):389-396. PubMed ID: 31102719
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Liver stiffness measurement in children using FibroScan: feasibility study and comparison with Fibrotest, aspartate transaminase to platelets ratio index, and liver biopsy.
    de Lédinghen V; Le Bail B; Rebouissoux L; Fournier C; Foucher J; Miette V; Castéra L; Sandrin L; Merrouche W; Lavrand F; Lamireau T
    J Pediatr Gastroenterol Nutr; 2007 Oct; 45(4):443-50. PubMed ID: 18030211
    [TBL] [Abstract][Full Text] [Related]  

  • 8. FibroTest and FibroScan for the prediction of hepatitis C-related fibrosis: a systematic review of diagnostic test accuracy.
    Shaheen AA; Wan AF; Myers RP
    Am J Gastroenterol; 2007 Nov; 102(11):2589-600. PubMed ID: 17850410
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Progression of Liver Fibrosis in HIV/HCV Co-Infection: A Comparison between Non-Invasive Assessment Methods and Liver Biopsy.
    Schmid P; Bregenzer A; Huber M; Rauch A; Jochum W; Müllhaupt B; Vernazza P; Opravil M; Weber R;
    PLoS One; 2015; 10(9):e0138838. PubMed ID: 26418061
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Diagnostic and prognostic values of noninvasive biomarkers of fibrosis in patients with alcoholic liver disease.
    Naveau S; Gaudé G; Asnacios A; Agostini H; Abella A; Barri-Ova N; Dauvois B; Prévot S; Ngo Y; Munteanu M; Balian A; Njiké-Nakseu M; Perlemuter G; Poynard T
    Hepatology; 2009 Jan; 49(1):97-105. PubMed ID: 19053048
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparison of ELF, FibroTest and FibroScan for the non-invasive assessment of liver fibrosis.
    Friedrich-Rust M; Rosenberg W; Parkes J; Herrmann E; Zeuzem S; Sarrazin C
    BMC Gastroenterol; 2010 Sep; 10():103. PubMed ID: 20828377
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Fibroscan can avoid liver biopsy in Indian patients with chronic hepatitis B.
    Goyal R; Mallick SR; Mahanta M; Kedia S; Shalimar ; Dhingra R; Sharma H; Das P; Datta Gupta S; Panda S; Acharya SK
    J Gastroenterol Hepatol; 2013 Nov; 28(11):1738-45. PubMed ID: 23808910
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Validation of the new 2021 EASL algorithm for the noninvasive diagnosis of advanced fibrosis in NAFLD.
    Canivet CM; Costentin C; Irvine KM; Delamarre A; Lannes A; Sturm N; Oberti F; Patel PJ; Decaens T; Irles-Depé M; Fouchard I; Hermabessière P; Roux M; Barthelon J; Calès P; Powell EE; de Ledinghen V; Boursier J
    Hepatology; 2023 Mar; 77(3):920-930. PubMed ID: 35822302
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Non-invasive testing and risk-stratification in patients with MASLD.
    Zoncapè M; Liguori A; Tsochatzis EA
    Eur J Intern Med; 2024 Apr; 122():11-19. PubMed ID: 38246813
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparison of liver biopsy and noninvasive techniques for liver fibrosis assessment in patients infected with HCV-genotype 4 in Egypt.
    Bonnard P; Elsharkawy A; Zalata K; Delarocque-Astagneau E; Biard L; Le Fouler L; Hassan AB; Abdel-Hamid M; El-Daly M; Gamal ME; El Kassas M; Bedossa P; Carrat F; Fontanet A; Esmat G
    J Viral Hepat; 2015 Mar; 22(3):245-53. PubMed ID: 25073725
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cost-comparison analysis of FIB-4, ELF and fibroscan in community pathways for non-alcoholic fatty liver disease.
    Srivastava A; Jong S; Gola A; Gailer R; Morgan S; Sennett K; Tanwar S; Pizzo E; O'Beirne J; Tsochatzis E; Parkes J; Rosenberg W
    BMC Gastroenterol; 2019 Jul; 19(1):122. PubMed ID: 31296161
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Assessment of liver fibrosis with transient elastography and FibroTest in patients treated with methotrexate for chronic inflammatory diseases: a case-control study.
    Laharie D; Seneschal J; Schaeverbeke T; Doutre MS; Longy-Boursier M; Pellegrin JL; Chabrun E; Villars S; Zerbib F; de Lédinghen V
    J Hepatol; 2010 Dec; 53(6):1035-40. PubMed ID: 20801541
    [TBL] [Abstract][Full Text] [Related]  

  • 18. ARFI, FibroScan, ELF, and their combinations in the assessment of liver fibrosis: a prospective study.
    Crespo G; Fernández-Varo G; Mariño Z; Casals G; Miquel R; Martínez SM; Gilabert R; Forns X; Jiménez W; Navasa M
    J Hepatol; 2012 Aug; 57(2):281-7. PubMed ID: 22521355
    [TBL] [Abstract][Full Text] [Related]  

  • 19. FibroScan, APRI, FIB4, and GUCI: Role in prediction of fibrosis and response to therapy in Egyptian patients with HCV infection.
    Yosry A; Fouad R; Alem SA; Elsharkawy A; El-Sayed M; Asem N; Hassan E; Ismail A; Esmat G
    Arab J Gastroenterol; 2016 Jun; 17(2):78-83. PubMed ID: 27353055
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The Enhanced Liver Fibrosis test maintains its diagnostic and prognostic performance in alcohol-related liver disease: a cohort study.
    Connoley D; Patel PJ; Hogan B; Tanwar S; Rhodes F; Parkes J; Burt A; Watkins J; Sievert W; Rosenberg W
    BMC Gastroenterol; 2021 Jun; 21(1):268. PubMed ID: 34182924
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.